Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
NCT04077515
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
92
Enrollment
OTHER
Sponsor class
Conditions
Hemangioma
Kaposiform Hemangioendothelioma
Interventions
DRUG:
Sirolimus(0.8mg/m2)
DRUG:
Sirolimus(0.7mg/m2)
Sponsor
Children's Hospital of Fudan University